(MENAFN- ABN Newswire) Oventus: Innovators in Sleep Apnoea Treatment
2018 AGM Presentation Brisbane, Nov 16, 2018 AEST (ABN Newswire) - Oventus Medical Ltd ( 75% of OSA sufferers
- Oct 18: O2Vent Optima(TM) registered with Australian TGA
- Oct 18: Released 4 clinical trial results bringing total data collected to 170 patients
Key strategic initiatives of FY2019
- As product development and clinical trials are finalised, Oventus is transitioning from an R&D focused company to a "go to market" / sales oriented company - with a restructured team
- Key parts of manufacturing process being outsourced to enable Oventus to be a "virtual company", while retaining management of data and software design (core to value proposition)
- Sales / marketing of 'Sleep Treatment Platform' shifted to focus on sleep channel
- Building out US team and rolling out US go to market strategy
- Further communicate outstanding clinical evidence which clearly differentiates Oventus as a new treatment modality
- Commercialising and launching products in late stage development, extending the reach of the Oventus treatment platform and reducing COGS
- Reducing fixed costs in business by 15-20% moving forward - significant steps already undertaken in FY2018
To view the full presentation, please visit:
http://abnnewswire.net/lnk/54HKABA9
About Oventus Medical Ltd
For more information on Oventus' Sleep Treatment Platform, please visit http://www.oventus.com
MENAFN1511201801110000ID1097704050
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.